Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature
Open Access
- 19 November 2015
- journal article
- review article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 11 (1) , 197-200
Abstract
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne-like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib-induced atypical skin reaction in a 73-year-old woman with advanced non-small cell lung cancer, who developed a squamous-crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.Keywords
This publication has 27 references indexed in Scilit:
- Epidermal EGFR Controls Cutaneous Host Defense and Prevents InflammationScience Translational Medicine, 2013
- Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR TherapyScience Translational Medicine, 2013
- A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysisRadiology and Oncology, 2013
- Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0Journal of the American Academy of Dermatology, 2012
- The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapiesJournal of the American Academy of Dermatology, 2011
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinionAnnals of Oncology, 2010
- Microbiological analysis of epidermal growth factor receptor inhibitor therapy‐associated paronychiaJournal of the European Academy of Dermatology and Venereology, 2010
- Chemotherapeutic agents and the skin: An updateJournal of the American Academy of Dermatology, 2008
- HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management ForumThe Oncologist, 2005